Clinical Trial Update: To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety and tolerability of AZD1656 in type 2 diabetes patients on insulin has completed. The trial was sponsored by AstraZeneca.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• AZD1656

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes | Phase 1 | Status: COMPLETED